Skip to main content
. 2022 Aug 23;13(4):159–171. doi: 10.14740/wjon1504

Table 2. Demography, and Clinical Characteristics of PI-NHL Patients in the Study.

Characteristics N (% or range)
Total 8,568
Median age in years (IQR) 66.5 (55 - 77)
  < 60 years 2,933 (34.23)
  ≥ 60 years 5,635 (65.77)
Sex
  Female 3,352 (39.12)
  Male 5,216 (60.88)
Ethnicity
  Non-Hispanic White 6,240 (72.83)
  Non-Hispanic Black 533 (6.22)
  Hispanic 967 (11.29)
  Others 828 (9.66)
Staging
  Stage 1 4,013 (46.84)
  Stage 2 2,329 (27.18)
  Stage 3 456 (5.32)
  Stage 4 1,770 (20.66)
Site
  Small intestine 4,696 (54.81)
  Large intestine 3,872 (45.19)
Histology
  Follicular lymphoma 1,563 (18.24)
  MALToma 1,160 (13.54)
  DLBCL 3,835 (44.76)
  Mantle cell lymphoma 447 (5.22)
  Burkitt lymphoma 344 (4.01)
  Other B-cell lymphoma 232 (2.71)
  T-Cell non-Hodgkin lymphoma 392 (4.58)
  Non-Hodgkin lymphoma, NOS 595 (6.94)
Treatment
  Chemotherapy only 2,018 (23.55)
  Surgery only 2,446 (28.55)
  Surgery and chemotherapy 2,506 (29.25)
  None 1,598 (18.65)
Year of diagnosis
  2000 - 2005 2,911 (33.98)
  2006 - 2010 2,815 (32.85)
  2011 - 2015 2,842 (33.17)

IQR: interquartile range; DLBCL: diffuse large B-cell lymphoma; NOS: not otherwise specified; PI-NHL: primary intestinal non-Hodgkin lymphoma; MALToma: mucosa-associated lymphoid tissue lymphoma.